肝细胞癌中雄激素受体过表达的意义及雄激素受体与雷帕霉素机制靶点交叉对话的机制
本研究发现约37%的肝细胞癌肿瘤细胞核中雄激素受体过表达,且与晚期疾病阶段和较差生存显著相关;雄激素受体过表达改变转录组、促进肿瘤生长并决定对恩杂鲁胺的治疗反应,但抑制雄激素受体会反馈激活AKT-mTOR信号,而mTOR通过抑制泛素依赖性雄激素受体降解促进其核表达,联合靶向雄激素受体和mTOR在体内显示协同抗肝细胞癌活性并减少肿瘤负荷。
要点
- 约37%的肝细胞癌肿瘤存在雄激素受体核过表达,与晚期疾病和较差生存显著相关。
- 单用恩杂鲁胺疗效有限,与反馈激活AKT-mTOR通路有关。
- 联合靶向雄激素受体和mTOR在体内显示协同抗肝细胞癌活性并减少肿瘤负荷。
核心结论
- 核雄激素受体过表达与肝细胞癌的进展和预后相关。
- 单用恩杂鲁胺因反馈激活AKT-mTOR通路而治疗效用有限。
- mTOR驱动核雄激素受体过表达。
- 联合靶向雄激素受体和mTOR是肝细胞癌有前景的治疗策略。
研究设计与样本
- 研究检测了肝细胞癌肿瘤中雄激素受体的表达,并在肝细胞癌细胞的体外和体内实验中分析了雄激素受体依赖的转录组、生长效应及对恩杂鲁胺的治疗反应。
主要发现
- 雄激素受体在约37%的肝细胞癌肿瘤细胞核中过表达,且与晚期疾病阶段和较差生存显著相关。
- 肝细胞癌细胞中雄激素受体过表达显著改变雄激素受体依赖的转录组,刺激肿瘤生长,并决定对恩杂鲁胺的治疗反应。
- 抑制雄激素受体会反馈激活AKT-mTOR信号。
- mTOR通过抑制泛素依赖性雄激素受体降解和增强雄激素受体核定位来促进核雄激素受体蛋白表达。
- 联合靶向雄激素受体和mTOR在体内显示显著协同抗肝细胞癌活性,并通过诱导凋亡减少肿瘤负荷。
临床怎么用
- 作者认为,联合靶向雄激素受体和mTOR是肝细胞癌有前景的治疗策略。
- 作者指出,单用恩杂鲁胺因反馈激活AKT-mTOR通路而治疗效用有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hepatocellular carcinoma (HCC) is a male-dominant cancer, and androgen receptor (AR) has been linked to the pathogenesis of HCC. However, AR expression and its precise role in HCC remain controversial. Moreover, previous antiandrogen and anti-AR clinical trials in HCC failed to demonstrate clinical benefits. In this study, we found that AR is overexpressed in the nucleus of approximately 37% of HCC tumors, which is significantly associated with advanced disease stage and poor survival. AR overexpression in HCC cells markedly alters AR-dependent transcriptome, stimulates oncogenic growth, and determines therapeutic response to enzalutamide, a second generation of AR antagonist. However, AR inhibition evokes feedback activation of AKT-mTOR (mechanistic target of rapamycin) signaling, a central regulator for cell growth and survival. On the other hand, mTOR promotes nuclear AR protein expression by restraining ubiquitin-dependent AR degradation and enhancing AR nuclear localization, providing a mechanistic explanation for nuclear AR overexpression in HCC. Finally, cotargeting AR and mTOR shows significant synergistic anti-HCC activity and decreases tumor burden by inducing apoptosis in vivo. CONCLUSION: Nuclear AR overexpression is associated with the progression and prognosis of HCC. However, enzalutamide alone has limited therapeutic utility attributed to feedback activation of the AKT-mTOR pathway. Moreover, mTOR drives nuclear AR overexpression. Cotargeting AR and mTOR is a promising therapeutic strategy for HCC. (Hepatology 2018;67:2271-2286).
引用
- Zhang H, Li XX, Yang Y, et al. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. Hepatology. 2018. PMID: 29220539. doi:10.1002/hep.29715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。